Harvard Pilgrim secures discount on Gilead’s newest hep C drug

Harvard Pilgrim Health Care, one of the largest not-for-profit health insurers in New England, said it will save millions of dollars in hepatitis C drug costs through its negotiated pricing discount from pharmaceutical giant Gilead. Wellesley, Mass.-based Harvard Pilgrim will receive a lower price for Harvoni, Gilead’s newest hepatitis C drug. In exchange, the one-tablet Harvoni will become the preferred drug for the insurer’s covered patients who have hepatitis C genotype 1, the most common version of the liver disease.